EXS73565

· Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EXS73565, covering 2025-12-03 to 2025-12-03. Get the full timeline:

Most recent: Clinical Trial Update: Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies [Phase 1]